9月16日，康龙化成盘中上涨3.26%，报29.78港元，成交额1812.76万港元。
消息面上，CRO/CDMO板块延续强势，药明康德中报业绩大幅超预期并上调全年指引，持续验证行业高景气。康龙化成自身上半年营收75.95亿元，同比增长17.9%，其中CDMO收入同比增长32.8%，管理层将全年收入增长指引由12%-18%上调至15%-20%。近期大和、美银、大摩分别上调公司目标价至38.5、38.4、35.6港元，均维持买入或增持评级。此外，摩根大通、摩根士丹利、花旗集团近期均增持公司H股。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.